Back to Search Start Over

Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques

Authors :
Langley, Sarah R.
Willeit, Karin
Didangelos, Athanasios
Matic, Ljubica Perisic
Skroblin, Philipp
Barallobre-Barreiro, Javier
Lengquist, Mariette
Rungger, Gregor
Kapustin, Alexander
Kedenko, Ludmilla
Molenaar, Chris
Lu, Ruifang
Barwari, Temo
Suna, Gonca
Yin, Xiaoke
Iglseder, Bernhard
Paulweber, Bernhard
Willeit, Peter
Shalhoub, Joseph
Pasterkamp, Gerard
Davies, Alun H.
Monaco, Claudia
Hedin, Ulf
Shanahan, Catherine M.
Willeit, Johann
Kiechl, Stefan
Mayr, Manuel
Source :
Journal of Clinical Investigation. April, 2017, Vol. 127 Issue 4, p1546, 15 p.
Publication Year :
2017

Abstract

BACKGROUND. The identification of patients with high-risk atherosclerotic plaques prior to the manifestation of clinical events remains challenging. Recent findings question histology- and imaging-based definitions of the 'vulnerable plaque,' necessitating an improved approach for predicting onset of symptoms. METHODS. We performed a proteomics comparison of the vascular extracellular matrix and associated molecules in human carotid endarterectomy specimens from 6 symptomatic versus 6 asymptomatic patients to identify a protein signature for high-risk atherosclerotic plaques. Proteomics data were integrated with gene expression profiling of 121 carotid endarterectomies and an analysis of protein secretion by lipid-loaded human vascular smooth muscle cells. Finally, epidemiological validation of candidate biomarkers was performed in two community-based studies. RESULTS. Proteomics and at least one of the other two approaches identified a molecular signature of plaques from symptomatic patients that comprised matrix metalloproteinase 9, chitinase 3-like-1, S100 calcium binding protein A8 (S100A8), S100A9, cathepsin B, fibronectin, and galectin-3-binding protein. Biomarker candidates measured in 685 subjects in the Bruneck study were associated with progression to advanced atherosclerosis and incidence of cardiovascular disease over a 10-year follow-up period. A 4-biomarker signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D, and galectin-3binding protein) improved risk prediction and was successfully replicated in an independent cohort, the SAPHIR study. CONCLUSION. The identified 4-biomarker signature may improve risk prediction and diagnostics for the management of cardiovascular disease. Further, our study highlights the strength of tissue-based proteomics for biomarker discovery. FUNDING. UK: British Heart Foundation (BHF); King's BHF Center; and the National Institute for Health Research Biomedical Research Center based at Guy's and St Thomas' NHS Foundation Trust and King's College London in partnership with King's College Hospital. Austria: Federal Ministry for Transport, Innovation and Technology (BMVIT); Federal Ministry of Science, Research and Economy (BMWFW); Wirtschaftsagentur Wien; and Standortagentur Tirol.<br />Introduction Atherosclerosis is a chronic and progressive disease of the arterial wall and the main underlying cause of stroke, myocardial infarction (MI), and cardiac death (1, 2). The evolution of [...]

Details

Language :
English
ISSN :
00219738
Volume :
127
Issue :
4
Database :
Gale General OneFile
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsgcl.491093292
Full Text :
https://doi.org/10.1172/JCI86924